Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
about
Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell diseaseInterventions for protecting renal function in the perioperative periodAngiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell diseaseAngiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell diseaseBlasts from the pastRenal outcome in adults with renal insufficiency and irregular asymmetric kidneysGlomerular Function and Structure in Living Donors: Lessons from Single Nephron StudiesObesity and kidney protectionComparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study GroupProtection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathyImmunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetesRenal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive ratsSuramin alleviates glomerular injury and inflammation in the remnant kidneyGene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulationAddition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritisGlomerulosclerosis in the diet-induced obesity model correlates with sensitivity to nitric oxide inhibition but not glomerular hyperfiltration or hypertrophyInteraction of the renin angiotensin and cox systems in the kidney.Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.Altered renal kallikrein and renin gene expression in nephrotic rats and modulation by converting enzyme inhibition.Mechanisms underlying renoprotection during renin-angiotensin system blockade.Aminopeptidase-A. I. CDNA cloning and expression and localization in rat tissues.Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.Transient enalapril attenuates the reduction in glomerular filtration rate in prenatally programmed rats.ACE inhibitors in non-diabetic renal disease.Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass.Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity.Progressive renal insufficiency. Office strategies to prevent or slow progression of kidney disease.Need kidneys fail?Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the ratGlomerular hypertrophy aggravates epithelial cell injury in nephrotic rats.Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.Molecular mechanisms of renal allograft fibrosis.Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis.Blood pressure control early in diabetes: a balance between angiotensin II and nitric oxide.Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosisGlomerular sclerosis is prevented during urinary tract obstruction due to podocyte protection
P2860
Q24187284-7E18F2AD-AC6D-4780-9D36-AAFDDC0270F3Q24198115-28677CB7-D4BA-448A-9099-433F9EF559D5Q24198791-29AB0281-3C00-4C5E-8E6D-90A36940F417Q24236018-C722A4E4-5B75-4778-A7E4-AD97CEEAECA9Q24563415-94C4A334-2FF9-4D85-A32D-455EAF72A002Q24791709-121B7B96-9F6A-41DA-B9D6-93570C6F8A28Q26752679-04BA5D9C-A41D-4363-A6C0-B10317F6F931Q27005818-841C8D01-3DB0-4C50-9970-B690F949E259Q28334898-9AB9706F-160F-41DF-BFB1-EAD3F935FF9BQ28361081-EB811027-CCAE-4F40-87C0-6DC90AE6A860Q28361901-90212264-57D8-4993-A5ED-9B315FA9DDF0Q28363418-35072535-6683-4EF2-A0A3-8E35440FFEA0Q28377508-70BF93CD-09B7-4AD4-BF6D-144CA035A021Q28482696-E7168F8C-C74B-42FC-899E-2BF641DFBC3CQ28505894-10F5A69D-3391-455F-AEBF-6D0883F5CFF1Q28565493-501AD41B-1D64-469F-8CDC-2FCEA72D9E0CQ28608232-7DE4CFE3-6D4E-46D7-B6A2-0217B40532A7Q30276943-47274EBB-9CF1-41EE-84EC-115D5BE08297Q30429844-56077398-FFFA-4242-8C6C-4DF7EE033EBDQ30449285-EE8A02BF-3D5E-44C8-B6B5-FBC22A73711CQ32032668-8C477B21-8604-443D-BFD3-4098B71878A7Q33179693-F7F7913B-27E4-4811-B521-914D63A8D1F0Q33404886-0C592321-3F36-409E-B762-6DFEAFBF4222Q33612378-4517F601-1034-4313-BC65-6C8435C140A1Q33614288-E5BF2483-E92F-463E-9A51-F2D817B98CE9Q33641557-C078EDE3-16FA-4A64-9246-50239ED8BB2FQ33727750-03F3C623-26C7-4C6F-8CD4-E7CE91C8A26AQ33808763-DEAA0596-0D66-40ED-82CC-6537E34072D7Q33983309-F1A1ADB7-E48A-4FC3-B72C-54D32CB5DF34Q34194397-71AE91F1-5E41-4091-8FDE-FD09170EA21DQ34243271-FCA2B871-25A0-4262-A6FB-E4EBE4A46707Q34247811-C6912095-6835-4F32-8675-164F14CF2404Q34331403-CE46794C-AF42-40AD-ABF2-24D73F18710FQ34421501-5AE073D0-DC79-4D66-A321-F7D9EAB335ADQ34488558-8CC6259C-21C5-4C91-B1A6-23D5754D1821Q34558136-ABFAF85F-A34F-4CA9-B8CA-062643F6C5C4Q34572586-6D967E63-1587-46CE-ABA0-4388BBB8CF2AQ34595011-9C3F07A4-7F4E-48B7-820F-54086588030DQ34604503-4C974B37-35B4-4F69-99C3-A717DE23859DQ34719120-D8C626AE-916A-4979-BB1C-5049DDACD3F3
P2860
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
description
1986 nî lūn-bûn
@nan
1986 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Therapeutic advantage of conve ...... stemic hypertension in the rat
@ast
Therapeutic advantage of conve ...... stemic hypertension in the rat
@en
Therapeutic advantage of conve ...... stemic hypertension in the rat
@nl
type
label
Therapeutic advantage of conve ...... stemic hypertension in the rat
@ast
Therapeutic advantage of conve ...... stemic hypertension in the rat
@en
Therapeutic advantage of conve ...... stemic hypertension in the rat
@nl
prefLabel
Therapeutic advantage of conve ...... stemic hypertension in the rat
@ast
Therapeutic advantage of conve ...... stemic hypertension in the rat
@en
Therapeutic advantage of conve ...... stemic hypertension in the rat
@nl
P2093
P2860
P356
P1476
Therapeutic advantage of conve ...... stemic hypertension in the rat
@en
P2093
B M Brenner
H G Rennke
S Anderson
P2860
P304
P356
10.1172/JCI112528
P407
P577
1986-06-01T00:00:00Z